Detection panel for follicular lymphoma prognosis evaluation based on circulating free DNA mutation, kit and application

Abstract

The invention discloses a detection panel for prognosis evaluation of follicular lymphoma based on circulating free DNA mutation, a kit and application. The detection panel comprises detection of a mutation gene related to follicular lymphoma prognosis. The invention provides a non-invasive detection method for prognosis evaluation of follicular lymphoma, and the non-invasive detection method has clinical application value so as to better guide treatment and improve prognosis of FL patients. A gene combination closely related to follicular lymphoma is creatively selected, based on a second-generation sequencing technology, the detection and analysis content comprises the following steps: performing second-generation detection on plasma cfDNA (plasma cfDNA), paraffin lymphoma tissue DNA (tumor tissue gDNA) and granulocyte gDNA of an FL clinical patient, and the gene combination disclosed by the invention has guiding significance on prognosis evaluation and treatment and has a good application prospect. And more prognosis evaluation dimensions are provided for doctors.

Description

technical field [0001] The invention belongs to the technical field of follicular lymphoma gene mutation detection, and in particular relates to a detection panel, kit and application for follicular lymphoma prognosis evaluation based on circulating free DNA mutation. Background technique [0002] Efficacy and prognosis evaluation has important clinical significance in tumor treatment, and its evaluation methods and methods are various. Currently, the diagnosis and prognostic assessment of follicular lymphoma require histological, immunohistochemical (eg, CD19, CD20 staining), and molecular genetic analyses of biopsies and tumor tissue obtained by invasive procedures (eg, biopsy) slice. However, biopsies obtained by invasive methods have several disadvantages: [0003] (1) Patients may experience pain and other complications associated with invasive biopsy; [0004] (2) Tumor biopsy may be difficult to obtain, and repeated sampling is extremely difficult; [0005] (3) Du...

AI Technical Summary

Problems solved by technology

[0003] (1) Patients may experience pain and other complications associated with invasive biopsy;

[0004] (2) Tumor biopsy may be difficult to obtain, and repeated sampling is extremely difficult;

[0005] (3) Due to the heterogeneity of the tumor, the genetic overview of the entire tumor tissue cannot be obtained;

[0006] (4) Unable to dynamically monitor the response to immunochemotherapy for follicular lymphoma

Current non-invasive methods (eg, PET, PET-CT) for diagnosis and staging of follicular lymphoma are expensive and cannot exclude false-positive results, and imaging studies are not a substitute for lymphoma tissue biopsy

Images